The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...
Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.
Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...
HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...
The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...
The FDA granted the approval of Hympavzi to Pfizer Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback